Cargando…
First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
OBJECTIVE: Upacicalcet is a new renally excreted and injectable calcimimetic agent. We evaluated the pharmacokinetics, pharmacodynamics, safety, and tolerability of single and multiple intravenous administration of upacicalcet in patients with secondary hyperparathyroidism undergoing hemodialysis. M...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439990/ https://www.ncbi.nlm.nih.gov/pubmed/35763247 http://dx.doi.org/10.1007/s40262-022-01139-w |
_version_ | 1784782211092840448 |
---|---|
author | Kazama, Junichiro James Koiwa, Fumihiko Yokoyama, Keitaro Fukagawa, Masafumi Asano, Kenji Honda, Daisuke Akizawa, Tadao |
author_facet | Kazama, Junichiro James Koiwa, Fumihiko Yokoyama, Keitaro Fukagawa, Masafumi Asano, Kenji Honda, Daisuke Akizawa, Tadao |
author_sort | Kazama, Junichiro James |
collection | PubMed |
description | OBJECTIVE: Upacicalcet is a new renally excreted and injectable calcimimetic agent. We evaluated the pharmacokinetics, pharmacodynamics, safety, and tolerability of single and multiple intravenous administration of upacicalcet in patients with secondary hyperparathyroidism undergoing hemodialysis. METHODS: This study was a multicenter, randomized, placebo-controlled, double-blinded, dose-escalation study consisting of a single-dose study and a multiple-dose study. The single-dose study consisted of seven dose steps from 0.025 to 0.8 mg. For each step, six patients were randomly assigned 2:1 to receive upacicalcet or a placebo. The multiple-dose study occurred over 3 weeks in three-dose steps from 0.05 to 0.2 mg. For each step, 12 patients were randomly assigned 3:1 to receive upacicalcet or a placebo. RESULTS: The plasma concentration of upacicalcet increased in a dose-dependent manner and was maintained for the next dialysis. Upacicalcet was approximately 80% removed by a single dialysis and did not increase in the plasma concentration with repeated administration. Serum intact parathyroid hormone and corrected calcium (Ca(2+)) levels tended to decrease in response to the plasma concentration of upacicalcet. In the single-dose study, upper gastrointestinal symptoms were observed as a non-serious and mild adverse drug reaction in the groups receiving upacicalcet ≥ 0.4 mg. In the multiple-dose study, abdominal discomfort occurred in each patient in the 0.1 mg and 0.2 mg groups. CONCLUSIONS: Upacicalcet for patients with secondary hyperparathyroidism undergoing hemodialysis could be a calcimimetic agent that acts in a dose-dependent manner and persistently until the next dialysis session. No safety or tolerability issues specific to upacicalcet were found. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40262-022-01139-w. |
format | Online Article Text |
id | pubmed-9439990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-94399902022-09-04 First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties Kazama, Junichiro James Koiwa, Fumihiko Yokoyama, Keitaro Fukagawa, Masafumi Asano, Kenji Honda, Daisuke Akizawa, Tadao Clin Pharmacokinet Original Research Article OBJECTIVE: Upacicalcet is a new renally excreted and injectable calcimimetic agent. We evaluated the pharmacokinetics, pharmacodynamics, safety, and tolerability of single and multiple intravenous administration of upacicalcet in patients with secondary hyperparathyroidism undergoing hemodialysis. METHODS: This study was a multicenter, randomized, placebo-controlled, double-blinded, dose-escalation study consisting of a single-dose study and a multiple-dose study. The single-dose study consisted of seven dose steps from 0.025 to 0.8 mg. For each step, six patients were randomly assigned 2:1 to receive upacicalcet or a placebo. The multiple-dose study occurred over 3 weeks in three-dose steps from 0.05 to 0.2 mg. For each step, 12 patients were randomly assigned 3:1 to receive upacicalcet or a placebo. RESULTS: The plasma concentration of upacicalcet increased in a dose-dependent manner and was maintained for the next dialysis. Upacicalcet was approximately 80% removed by a single dialysis and did not increase in the plasma concentration with repeated administration. Serum intact parathyroid hormone and corrected calcium (Ca(2+)) levels tended to decrease in response to the plasma concentration of upacicalcet. In the single-dose study, upper gastrointestinal symptoms were observed as a non-serious and mild adverse drug reaction in the groups receiving upacicalcet ≥ 0.4 mg. In the multiple-dose study, abdominal discomfort occurred in each patient in the 0.1 mg and 0.2 mg groups. CONCLUSIONS: Upacicalcet for patients with secondary hyperparathyroidism undergoing hemodialysis could be a calcimimetic agent that acts in a dose-dependent manner and persistently until the next dialysis session. No safety or tolerability issues specific to upacicalcet were found. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40262-022-01139-w. Springer International Publishing 2022-06-28 2022 /pmc/articles/PMC9439990/ /pubmed/35763247 http://dx.doi.org/10.1007/s40262-022-01139-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Article Kazama, Junichiro James Koiwa, Fumihiko Yokoyama, Keitaro Fukagawa, Masafumi Asano, Kenji Honda, Daisuke Akizawa, Tadao First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties |
title | First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties |
title_full | First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties |
title_fullStr | First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties |
title_full_unstemmed | First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties |
title_short | First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties |
title_sort | first-in-patient phase i/ii study of upacicalcet in japanese patients with secondary hyperparathyroidism undergoing hemodialysis: pharmacokinetic and pharmacodynamic properties |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439990/ https://www.ncbi.nlm.nih.gov/pubmed/35763247 http://dx.doi.org/10.1007/s40262-022-01139-w |
work_keys_str_mv | AT kazamajunichirojames firstinpatientphaseiiistudyofupacicalcetinjapanesepatientswithsecondaryhyperparathyroidismundergoinghemodialysispharmacokineticandpharmacodynamicproperties AT koiwafumihiko firstinpatientphaseiiistudyofupacicalcetinjapanesepatientswithsecondaryhyperparathyroidismundergoinghemodialysispharmacokineticandpharmacodynamicproperties AT yokoyamakeitaro firstinpatientphaseiiistudyofupacicalcetinjapanesepatientswithsecondaryhyperparathyroidismundergoinghemodialysispharmacokineticandpharmacodynamicproperties AT fukagawamasafumi firstinpatientphaseiiistudyofupacicalcetinjapanesepatientswithsecondaryhyperparathyroidismundergoinghemodialysispharmacokineticandpharmacodynamicproperties AT asanokenji firstinpatientphaseiiistudyofupacicalcetinjapanesepatientswithsecondaryhyperparathyroidismundergoinghemodialysispharmacokineticandpharmacodynamicproperties AT hondadaisuke firstinpatientphaseiiistudyofupacicalcetinjapanesepatientswithsecondaryhyperparathyroidismundergoinghemodialysispharmacokineticandpharmacodynamicproperties AT akizawatadao firstinpatientphaseiiistudyofupacicalcetinjapanesepatientswithsecondaryhyperparathyroidismundergoinghemodialysispharmacokineticandpharmacodynamicproperties |